Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart, Anlotinib and Chemotherapy in ES-SCLC
NCT06931145Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benmelstobart in small cell lung cancer (SCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression Free Survival at 7 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06931145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931145.